Chunli Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chunli Li has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Yang Hou
Key Laboratory of Biomass Chemical Engineering of Ministry of Education College of Chemical and Biological Engineering Zhejiang University Hangzhou China
4 shared publications - Yu Shi
Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, China
4 shared publications - Ling Zhang
DAMO Academy, Alibaba Group, Washington DC, USA
3 shared publications - Xiaoming Zhang
School of Computing and Artificial Intelligence, Southwest Jiaotong University, Chengdu, China
3 shared publications Chaoya Zhang
Department of Radiology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications- Jiandong Yin
Department of Radiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
2 shared publications
Latest Publications
- 19 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3717-3729
Large-scale AI-guided liver malignancy diagnosis: multicenter study and a single-arm trial
Liver malignancies are frequently evaluated on contrast-enhanced computed tomography (CE-CT), but missed or delayed diagnoses remain a clinically important challenge in high-volume, real-world radiology workflows, highlighting the need for scalable diagnostic safety net approaches. To address this, we developed the Liver DiagnOsis Network (LiON), a CE-CT-based artificial intelligence (AI) system that supports flexible multiphase processing, clinical data integration and workflow-compatible liver malignancy diagnosis. LiON was trained on 6,443 patients and retrospectively validated across 22,251 patients from multicenter and real-world cohorts. LiON achieved high performance for malignancy diagnosis, with an area under the receiver operating characteristic curve (AUC) of 0.975 (95% confidence interval (CI): 0.971−0.979), and maintained robust performance in real-world cohorts and among patients with hepatic steatosis (AUC 0.971, 95% CI: 0.952−0.985) and cirrhosis (AUC 0.924, 95% CI: 0.901−0.946). We then conducted a single-arm trial in 10,333 patients in routine clinical practice, in which LiON functioned as an additional AI reader within the existing clinical workflow. The trial met its primary endpoint, defined as an AUC for malignancy diagnosis with the lower bound of the 95% CI exceeding 0.900, achieving an AUC of 0.952 (95% CI: 0.942−0.961). Secondary outcomes demonstrated that AI−human collaboration identified 51 previously overlooked lesions (15 malignancies) and triggered 37 amended radiology reports, 22 multidisciplinary team escalations and clinical management changes in a subset of patients. These findings suggest that AI, when deployed as a workflow-compatible diagnostic support, may help reduce missed or delayed diagnoses and guide clinical interventions. Nevertheless, further evidence from prospective comparative studies across diverse healthcare systems is warranted to assess effects on clinical outcomes. ClinicalTrials.gov identifier: NCT07153783.
- 19 August 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (10) , 3717-3729
Large-scale AI-guided liver malignancy diagnosis: multicenter study and a single-arm trial
Liver malignancies are frequently evaluated on contrast-enhanced computed tomography (CE-CT), but missed or delayed diagnoses remain a clinically important challenge in high-volume, real-world radiology workflows, highlighting the need for scalable diagnostic safety net approaches. To address this, we developed the Liver DiagnOsis Network (LiON), a CE-CT-based artificial intelligence (AI) system that supports flexible multiphase processing, clinical data integration and workflow-compatible liver malignancy diagnosis. LiON was trained on 6,443 patients and retrospectively validated across 22,251 patients from multicenter and real-world cohorts. LiON achieved high performance for malignancy diagnosis, with an area under the receiver operating characteristic curve (AUC) of 0.975 (95% confidence interval (CI): 0.971−0.979), and maintained robust performance in real-world cohorts and among patients with hepatic steatosis (AUC 0.971, 95% CI: 0.952−0.985) and cirrhosis (AUC 0.924, 95% CI: 0.901−0.946). We then conducted a single-arm trial in 10,333 patients in routine clinical practice, in which LiON functioned as an additional AI reader within the existing clinical workflow. The trial met its primary endpoint, defined as an AUC for malignancy diagnosis with the lower bound of the 95% CI exceeding 0.900, achieving an AUC of 0.952 (95% CI: 0.942−0.961). Secondary outcomes demonstrated that AI−human collaboration identified 51 previously overlooked lesions (15 malignancies) and triggered 37 amended radiology reports, 22 multidisciplinary team escalations and clinical management changes in a subset of patients. These findings suggest that AI, when deployed as a workflow-compatible diagnostic support, may help reduce missed or delayed diagnoses and guide clinical interventions. Nevertheless, further evidence from prospective comparative studies across diverse healthcare systems is warranted to assess effects on clinical outcomes. ClinicalTrials.gov identifier: NCT07153783.
- Top Cited PapersOpen Access
- 11 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 1562
Multi-modal AI for opportunistic screening, staging and progression risk stratification of steatotic liver disease
The global rise in steatotic liver disease poses a significant public health challenge. While non-contrast computed tomography scans hold promise for opportunistic detection of steatotic liver disease, their potential for staging and risk assessment remains underexplored. Here we present a multimodal AI model trained on a large dataset, comprising of (n=968) histopathologically and (n=1103) radiologically confirmed cases, validated against both histology (n=660) and MRI-PDFF (n=375) gold standards, demonstrating high accuracy in detecting mild to severe steatosis (AUC: 0.904-0.929) and clinically significant fibrosis (AUC: 0.824-0.888). Furthermore, integrating the model into the standard clinical pathway improves primary risk screening in a retrospective patient cohort (n=1192), identifying 36% more patients at risk of fibrosis progression. Using Cox proportional hazard model, we observe that the intermediate-high risk patients identified by the optimized clinical pathway exhibits a significantly higher incidence of cirrhosis (hazard ratio: 5.54: 2.69-11.42), showcasing the model's potential for early detection and management of steatotic liver disease.
- 11 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 1562
Top Cited PapersOpen AccessMulti-modal AI for opportunistic screening, staging and progression risk stratification of steatotic liver disease
The global rise in steatotic liver disease poses a significant public health challenge. While non-contrast computed tomography scans hold promise for opportunistic detection of steatotic liver disease, their potential for staging and risk assessment remains underexplored. Here we present a multimodal AI model trained on a large dataset, comprising of (n=968) histopathologically and (n=1103) radiologically confirmed cases, validated against both histology (n=660) and MRI-PDFF (n=375) gold standards, demonstrating high accuracy in detecting mild to severe steatosis (AUC: 0.904-0.929) and clinically significant fibrosis (AUC: 0.824-0.888). Furthermore, integrating the model into the standard clinical pathway improves primary risk screening in a retrospective patient cohort (n=1192), identifying 36% more patients at risk of fibrosis progression. Using Cox proportional hazard model, we observe that the intermediate-high risk patients identified by the optimized clinical pathway exhibits a significantly higher incidence of cirrhosis (hazard ratio: 5.54: 2.69-11.42), showcasing the model's potential for early detection and management of steatotic liver disease.
- 24 December 2025
- Published by Elsevier in Medical Image Analysis
- Vol. 109, 103924
Non-contrast CT esophageal varices grading through clinical prior-enhanced multi-organ analysis
- 24 December 2025
- Published by Elsevier in Medical Image Analysis
- Vol. 109, 103924
Non-contrast CT esophageal varices grading through clinical prior-enhanced multi-organ analysis
- Open Access
- 17 October 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 77, 102881
Development of fully automated models for staging liver fibrosis using non-contrast MRI and artificial intelligence: a retrospective multicenter study
- 17 October 2024
- Published by Elsevier in eClinicalMedicine
- Vol. 77, 102881
Open AccessDevelopment of fully automated models for staging liver fibrosis using non-contrast MRI and artificial intelligence: a retrospective multicenter study
- Open Access
- 18 August 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (8) , 1491
Radiomics Nomogram Based on Radiomics Score from Multiregional Diffusion-Weighted MRI and Clinical Factors for Evaluating HER-2 2+ Status of Breast Cancer
This study aimed to establish and validate a radiomics nomogram using the radiomics score (rad-score) based on multiregional diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) features combined with clinical factors for evaluating HER-2 2+ status of breast cancer. A total of 223 patients were retrospectively included. Radiomic features were extracted from multiregional DWI and ADC images. Based on the intratumoral, peritumoral, and combined regions, three rad-scores were calculated using the logistic regression model. Independent parameters were selected among clinical factors and combined rad-score (com-rad-score) using multivariate logistic analysis and used to construct a radiomics nomogram. The performance of the nomogram was evaluated using calibration, discrimination, and clinical usefulness. The areas under the receiver operator characteristic curve (AUCs) of intratumoral and peritumoral rad-scores were 0.824/0.763 and 0.794/0.731 in the training and validation cohorts, respectively. Com-rad-score achieved the highest AUC (0.860/0.790) among three rad-scores. ER status and com-rad-score were selected to establish the nomogram, which yielded good discrimination (AUC: 0.883/0.848) and calibration. Decision curve analysis demonstrated the clinical value of the nomogram in the validation cohort. In conclusion, radiomics nomogram, including clinical factors and com-rad-score, showed favorable performance for evaluating HER-2 2+ status in breast cancer.
- 18 August 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (8) , 1491
Open AccessRadiomics Nomogram Based on Radiomics Score from Multiregional Diffusion-Weighted MRI and Clinical Factors for Evaluating HER-2 2+ Status of Breast Cancer
This study aimed to establish and validate a radiomics nomogram using the radiomics score (rad-score) based on multiregional diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) features combined with clinical factors for evaluating HER-2 2+ status of breast cancer. A total of 223 patients were retrospectively included. Radiomic features were extracted from multiregional DWI and ADC images. Based on the intratumoral, peritumoral, and combined regions, three rad-scores were calculated using the logistic regression model. Independent parameters were selected among clinical factors and combined rad-score (com-rad-score) using multivariate logistic analysis and used to construct a radiomics nomogram. The performance of the nomogram was evaluated using calibration, discrimination, and clinical usefulness. The areas under the receiver operator characteristic curve (AUCs) of intratumoral and peritumoral rad-scores were 0.824/0.763 and 0.794/0.731 in the training and validation cohorts, respectively. Com-rad-score achieved the highest AUC (0.860/0.790) among three rad-scores. ER status and com-rad-score were selected to establish the nomogram, which yielded good discrimination (AUC: 0.883/0.848) and calibration. Decision curve analysis demonstrated the clinical value of the nomogram in the validation cohort. In conclusion, radiomics nomogram, including clinical factors and com-rad-score, showed favorable performance for evaluating HER-2 2+ status in breast cancer.